2008 Volume 20 Issue 1 Pages 7-12
Purpose: To assess the efficacy of linac-based stereotactic radiotherapy (SRT) with micro-multileaf collimator in patients with brain metastases.
Patients and Methods: Data of 96 metastatic brain lesions of brain metastases in 60 patients treated by SRT between September 2003 and December 2005 were analyzed. The primary sites were lung (42 patients), breast (4 patients), colon (4 patients), and others (10 patients). In the treatment planning, PTV was defined as enhanced lesion (=GTV) plus 3 mm margin. To the isocenters of PTV, total dose of 39-42 Gy with 3 fractions were delivered.
Results: The median survival after SRT was 15.1 months. The 1-year and 2-year survival rates were 56%, 36%, respectively. The local control rate was 86.2% with no serious adverse effects. After the treatment of SRT, new brain metastases and/or meningeal carcinomatosis were detected in approximately half of patients.
Conclusion: SRT with a micro-multileaf collimator is an effective and safe modality in the treating patients with brain metastases. (Article in Japanese)
